Compare · ELV vs GH
ELV vs GH
Side-by-side comparison of Elevance Health Inc. (ELV) and Guardant Health Inc. (GH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and GH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.84B, about 4.5x GH ($20.52B).
- Over the past year, ELV is up 29.9% and GH is up 57.4% - GH leads by 27.6 points.
- GH has been more active in the news (21 items in the past 4 weeks vs 4 for ELV).
- GH has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Guardant Health Inc.
- Price
- -
- -
- Market cap
- $92.84B
- $20.52B
- 1M return
- +0.28%
- -8.52%
- 1Y return
- +29.86%
- +57.41%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 4
- 21
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Latest ELV
- AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.’s New Shelf Registration
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Digital Info Ofr Lavu Ratnakar sold $572,000 worth of shares (1,300 units at $440.00), decreasing direct ownership by 8% to 14,849 units (SEC Form 4)
- SEC Form S-3ASR filed by Elevance Health Inc.
- EVP & CFO Kaye Mark sold $4,658,357 worth of shares (10,584 units at $440.13) (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Names Jeff Park President of Carelon
- SEC Form 8-K filed by Elevance Health Inc.
- Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
- The Future of Healthcare: AI-Powered, Coordinated and Proactive Care
Latest GH
- Director Azar Alex M Ii converted options into 138 shares, increasing direct ownership by 15% to 1,031 units (SEC Form 4)
- Director Sayer Kevin R was granted 3,149 restricted stock units (SEC Form 4)
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New insider Sayer Kevin R claimed no ownership of stock in the company (SEC Form 3)
- Chief Accounting Officer Parks Robert was granted 18,893 restricted stock units (SEC Form 4)
- New insider Parks Robert claimed no ownership of stock in the company (SEC Form 3)
- Guardant Health Prices $500 Million Convertible Senior Notes Offering
- Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
- Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
- PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases